244 related articles for article (PubMed ID: 18815196)
1. Methylation of the suppressor of cytokine signaling 3 gene (SOCS3) in myeloproliferative disorders.
Fourouclas N; Li J; Gilby DC; Campbell PJ; Beer PA; Boyd EM; Goodeve AC; Bareford D; Harrison CN; Reilly JT; Green AR; Bench AJ
Haematologica; 2008 Nov; 93(11):1635-44. PubMed ID: 18815196
[TBL] [Abstract][Full Text] [Related]
2. [Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia].
Iványi JL; Marton E; Plander M
Orv Hetil; 2011 Nov; 152(45):1795-803. PubMed ID: 22011365
[TBL] [Abstract][Full Text] [Related]
3. The myeloproliferative disorder-associated JAK2 V617F mutant escapes negative regulation by suppressor of cytokine signaling 3.
Hookham MB; Elliott J; Suessmuth Y; Staerk J; Ward AC; Vainchenker W; Percy MJ; McMullin MF; Constantinescu SN; Johnston JA
Blood; 2007 Jun; 109(11):4924-9. PubMed ID: 17317861
[TBL] [Abstract][Full Text] [Related]
4. Megakaryocytic morphology and clinical parameters in essential thrombocythemia, polycythemia vera, and primary myelofibrosis with and without JAK2 V617F.
Vytrva N; Stacher E; Regitnig P; Zinke-Cerwenka W; Hojas S; Hubmann E; Porwit A; Bjorkholm M; Hoefler G; Beham-Schmid C
Arch Pathol Lab Med; 2014 Sep; 138(9):1203-9. PubMed ID: 25171702
[TBL] [Abstract][Full Text] [Related]
5. [Novel method in diagnosis of chronic myeloproliferative disorders--detection of JAK2 mutation].
Rajnai H; Bödör C; Reiniger L; Timár B; Csernus B; Szepesi A; Csomor J; Matolcsy A
Orv Hetil; 2006 Nov; 147(45):2175-9. PubMed ID: 17402211
[TBL] [Abstract][Full Text] [Related]
6. [Myeloproliferative diseases caused by JAK2 mutation].
Nagata K; Shimoda K
Rinsho Byori; 2009 Apr; 57(4):357-64. PubMed ID: 19489438
[TBL] [Abstract][Full Text] [Related]
7. Epigenetic inactivation of suppressors of cytokine signalling in Philadelphia-negative chronic myeloproliferative disorders.
Capello D; Deambrogi C; Rossi D; Lischetti T; Piranda D; Cerri M; Spina V; Rasi S; Gaidano G; Lunghi M
Br J Haematol; 2008 May; 141(4):504-11. PubMed ID: 18318760
[TBL] [Abstract][Full Text] [Related]
8. Histone deacetylases inhibitor sodium butyrate inhibits JAK2/STAT signaling through upregulation of SOCS1 and SOCS3 mediated by HDAC8 inhibition in myeloproliferative neoplasms.
Gao SM; Chen CQ; Wang LY; Hong LL; Wu JB; Dong PH; Yu FJ
Exp Hematol; 2013 Mar; 41(3):261-70.e4. PubMed ID: 23111066
[TBL] [Abstract][Full Text] [Related]
9. The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis--impact on disease phenotype.
Larsen TS; Pallisgaard N; Møller MB; Hasselbalch HC
Eur J Haematol; 2007 Dec; 79(6):508-15. PubMed ID: 17961178
[TBL] [Abstract][Full Text] [Related]
10. A gain-of-function mutation of JAK2 in myeloproliferative disorders.
Kralovics R; Passamonti F; Buser AS; Teo SS; Tiedt R; Passweg JR; Tichelli A; Cazzola M; Skoda RC
N Engl J Med; 2005 Apr; 352(17):1779-90. PubMed ID: 15858187
[TBL] [Abstract][Full Text] [Related]
11. The diagnosis and management of polycythemia vera, essential thrombocythemia, and primary myelofibrosis in the JAK2 V617F era.
Zhan H; Spivak JL
Clin Adv Hematol Oncol; 2009 May; 7(5):334-42. PubMed ID: 19521323
[TBL] [Abstract][Full Text] [Related]
12. Incidence and significance of the JAK2 V617F mutation in patients with chronic myeloproliferative disorders.
Langabeer SE; Ni Ainle F; Conneally E; Lawler M
Ir J Med Sci; 2007; 176(2):105-9. PubMed ID: 17440677
[TBL] [Abstract][Full Text] [Related]
13. Different involvement of the megakaryocytic lineage by the JAK2 V617F mutation in Polycythemia vera, essential thrombocythemia and chronic idiopathic myelofibrosis.
Hussein K; Brakensiek K; Buesche G; Buhr T; Wiese B; Kreipe H; Bock O
Ann Hematol; 2007 Apr; 86(4):245-53. PubMed ID: 17262192
[TBL] [Abstract][Full Text] [Related]
14. Aberrant signal transduction pathways in myeloproliferative neoplasms.
Kota J; Caceres N; Constantinescu SN
Leukemia; 2008 Oct; 22(10):1828-40. PubMed ID: 18769448
[TBL] [Abstract][Full Text] [Related]
15. The role of Janus Kinase 2 V617F mutation in extramedullary hematopoiesis of the spleen in neoplastic myeloid disorders.
Hsieh PP; Olsen RJ; O'Malley DP; Konoplev SN; Hussong JW; Dunphy CH; Perkins SL; Cheng L; Lin P; Chang CC
Mod Pathol; 2007 Sep; 20(9):929-35. PubMed ID: 17643100
[TBL] [Abstract][Full Text] [Related]
16. Epigenetic alteration of SOCS family members is a possible pathogenetic mechanism in JAK2 wild type myeloproliferative diseases.
Teofili L; Martini M; Cenci T; Guidi F; Torti L; Giona F; Foà R; Leone G; Larocca LM
Int J Cancer; 2008 Oct; 123(7):1586-92. PubMed ID: 18623127
[TBL] [Abstract][Full Text] [Related]
17. Phenotypic variations and new mutations in JAK2 V617F-negative polycythemia vera, erythrocytosis, and idiopathic myelofibrosis.
Williams DM; Kim AH; Rogers O; Spivak JL; Moliterno AR
Exp Hematol; 2007 Nov; 35(11):1641-6. PubMed ID: 17920755
[TBL] [Abstract][Full Text] [Related]
18. The first international meeting on V617F JAK2 mutation and its relevance in Philadelphia-negative myeloproliferative disorders.
Kiladjian JJ; Casadevall N; Vainchenker W; Fenaux P
Pathol Biol (Paris); 2007 Mar; 55(2):85-7. PubMed ID: 16901656
[TBL] [Abstract][Full Text] [Related]
19. Correlations between Janus kinase 2 V617F allele burdens and clinicohematologic parameters in myeloproliferative neoplasms.
Ha JS; Kim YK; Jung SI; Jung HR; Chung IS
Ann Lab Med; 2012 Nov; 32(6):385-91. PubMed ID: 23130336
[TBL] [Abstract][Full Text] [Related]
20. A sensitive and reliable semi-quantitative real-time PCR assay to detect JAK2 V617F in blood.
Poodt J; Fijnheer R; Walsh IB; Hermans MH
Hematol Oncol; 2006 Dec; 24(4):227-33. PubMed ID: 17006961
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
